Classes
DEA Class; Rx
Common Brand Names; Osphena
- Selective Estrogen Receptor Modulators
Description
Oral estrogen receptor agonist/antagonist (selective estrogen-receptor modulator, or SERM)
Used to treat moderate to severe vaginal dryness and dyspareunia, which are symptoms of vulvar and vaginal atrophy due to menopause
Boxed warning alerting to estrogen-like activity that may encourage endometrial hyperplasia in women with an intact uterus and a risk for thrombotic events
Indications
Indicated for the treatment of moderate to severe vaginal dryness and dyspareunia, symptoms of atrophic vaginitis due to menopause.
Contraindications
Undiagnosed abnormal genital bleeding
Known or suspected estrogen-dependent neoplasia
History of, or active DVT or PE
History of, or active arterial thromboembolic disease (eg, stroke, MI)
Known or suspected pregnancy or women who may become pregnant
Documented hypersensitivity to drug or ingredients
Adverse Effects
- Hot flush (7.5%)
- Vaginal discharge (3.8%)
- Muscle spasms (3.2%)
- Hyperhidrosis (1.6%)
- Genital discharge (1.3%)
- Hypersensitivity
- Angioedema
- Rash
- Rash, erythematous
- Generalized rash
- Pruritus
- Urticaria
- Neoplasms: Benign, malignant and unspecified, endometrial hyperplasia, endometrial cancer
- Vascular disorders: Deep vein thrombosis, thrombosis, pulmonary embolism
Warnings
Manage risk factors for cardiovascular disorders, arterial vascular disease (eg, hypertension, DM, smoking, hypercholesterolemia, obesity), and/or venous thromboembolism to reduce risk for progression to serious disease
Increased risk of stroke reported in year 1 and persisted; should thromboembolic or hemorrhagic stroke occur or be suspected, therapy should be discontinued immediately
Venous thromboembolism (VTE) reported; if VTE occurs or suspected, discontinue immediately; when possible, discontinue therapy 4-6 weeks before surgery of the type associated with thromboembolism during prolonged periods of immobilization
Increased risk for endometrial hyperplasia (see Black Box Warnings)
Has not been studied in women with breast cancer; do not use with known or suspected breast cancer or history of breast cancer
Do not use with severe hepatic impairment (not studied)
May initiate or increase occurrence of hot flashes in some women
Pregnancy and Lactation
Contraindicated in women who are or may become pregnant; if a woman becomes pregnant while taking this drug, she should be apprised of the potential hazard to a fetus
Unknown if excreted in human breast milk
Do not breastfeed
Maximum Dosage
60 mg/day PO.
60 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Not indicated.
How supplied
Ospemifene
tablet
- 60mg